Getting the Timing Right: Controlling BCL-2 Inhibition as an Antifibrotic Therapy

Am J Respir Cell Mol Biol. 2024 Apr;70(4):231-232. doi: 10.1165/rcmb.2023-0436ED.

Authors

Joseph C Cooley^{1

2}, Elizabeth F Redente^{2

3}

Affiliations

¹ Department of Medicine National Jewish Health Denver, Colorado.
² Department of Medicine University of Colorado School of Medicine Aurora, Colorado.
³ Department of Pediatrics National Jewish Health Denver, Colorado.

PMID: 38259233
DOI: 10.1165/rcmb.2023-0436ED

No abstract available

Publication types

Editorial
Comment

MeSH terms

Endoplasmic Reticulum Stress
Endoribonucleases
Humans
Protein Serine-Threonine Kinases
Proto-Oncogene Proteins c-bcl-2
Pulmonary Fibrosis*

Substances

Endoribonucleases
Protein Serine-Threonine Kinases
Proto-Oncogene Proteins c-bcl-2